Interactive Effects of HDAC Inhibitors and TRAIL on Apoptosis Are Associated with Changes in Mitochondrial Functions and Expressions of Cell Cycle Regulatory Genes in Multiple Myeloma

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2005 Jul 20

PMID 16026644

Citations 57

Authors

Tamer E Fandy

Sharmila Shankar

Douglas D Ross

Edward Sausville

Rakesh K Srivastava

Affiliations

Soon will be listed here.

Abstract

In this study, we have evaluated the cytotoxic effect of combining two HDAC inhibitors, SAHA and TSA, with TRAIL in human multiple myeloma cell lines. Low doses of SAHA or TSA enhanced the cytotoxic and apoptotic effects of TRAIL and upregulated the surface expression of TRAIL death receptors (DR4 and/or DR5). SAHA and TSA induced G1 phase cell cycle growth arrest by upregulating p21(WAF1) and p27(Kip1) expression and by inhibiting E2F transcriptional activity. The enhanced TRAIL effect after pretreatment with HDAC inhibitors was consistent with the upregulation of the proapoptotic Bcl-2 family members (Bim, Bak, Bax, Noxa, and PUMA), the downregulation of the anti-apoptotic members of the Bcl-2 family (Bcl-2 and Bcl-X(L)), and IAPs. SAHA and TSA dissipated the mitochondrial membrane potential and enhanced the release of Omi/HtrA2 and AIF from the mitochondria to the cytosol. The cytotoxic effect of both SAHA and TSA was caspase- and calpain-independent. Inhibition of NF(kappa)B activation by the proteasome inhibitor, MG132, enhanced the apoptotic effect of TSA. Our study demonstrated the enhancing effects of HDAC inhibitors on apoptosis when combined with TRAIL and, for the first time, emphasized the role of AIF in mediating the cytotoxic effects of HDAC inhibitors.

Citing Articles

Born to survive: how cancer cells resist CAR T cell therapy.

Lemoine J, Ruella M, Houot R J Hematol Oncol. 2021; 14(1):199.

PMID: 34809678 PMC: 8609883. DOI: 10.1186/s13045-021-01209-9.

Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing.

Lemoine J, Ruella M, Houot R Clin Cancer Res. 2021; 27(23):6298-6306.

PMID: 34253582 PMC: 11260069. DOI: 10.1158/1078-0432.CCR-21-1559.

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity.

Bagratuni T, Patseas D, Mavrianou-Koutsoukou N, Liacos C, Sklirou A, Rousakis P Cancers (Basel). 2020; 12(10).

PMID: 33028016 PMC: 7601861. DOI: 10.3390/cancers12102864.

Effects of β-carotene on Expression of Selected MicroRNAs, Histone Acetylation, and DNA Methylation in Colon Cancer Stem Cells.

Kim D, Kim Y, Kim Y J Cancer Prev. 2020; 24(4):224-232.

PMID: 31950022 PMC: 6951318. DOI: 10.15430/JCP.2019.24.4.224.

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Cheng Y, He C, Wang M, Ma X, Mo F, Yang S Signal Transduct Target Ther. 2019; 4:62.

PMID: 31871779 PMC: 6915746. DOI: 10.1038/s41392-019-0095-0.

References

Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams R . E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 1998; 12(14):2120-30. PMC: 317011. DOI: 10.1101/gad.12.14.2120. View

Reddy P, Maeda Y, Hotary K, Liu C, Reznikov L, Dinarello C . Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A. 2004; 101(11):3921-6. PMC: 374345. DOI: 10.1073/pnas.0400380101. View

Susin S, Lorenzo H, Zamzami N, Marzo I, Snow B, Brothers G . Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999; 397(6718):441-6. DOI: 10.1038/17135. View

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

Chopin V, Slomianny C, Hondermarck H, Le Bourhis X . Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res. 2004; 298(2):560-73. DOI: 10.1016/j.yexcr.2004.04.038. View

Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta C . Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis. 2004; 9(5):573-82. DOI: 10.1023/B:APPT.0000038036.31271.50. View

Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T . Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 2004; 23(37):6261-71. DOI: 10.1038/sj.onc.1207830. View

Boehrer S, Brieger A, Schaaf S, Kukoc-Zivojnov N, Nowak D, Ruthardt M . In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis. Leuk Lymphoma. 2004; 45(7):1445-51. DOI: 10.1080/10428190410001663617. View

Moore P, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M . Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2004; 1693(3):167-76. DOI: 10.1016/j.bbamcr.2004.07.001. View

10.

Gao N, Dai Y, Rahmani M, Dent P, Grant S . Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol. 2004; 66(4):956-63. DOI: 10.1124/mol.104.002014. View

11.

McCarthy R, Fetterhoff T . Issues for quality assurance in clinical flow cytometry. Arch Pathol Lab Med. 1989; 113(6):658-66. View

12.

Yoshida M, Kijima M, Akita M, Beppu T . Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990; 265(28):17174-9. View

13.

Reers M, Smith T, Chen L . J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry. 1991; 30(18):4480-6. DOI: 10.1021/bi00232a015. View

14.

Roehm N, Rodgers G, Hatfield S, Glasebrook A . An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991; 142(2):257-65. DOI: 10.1016/0022-1759(91)90114-u. View

15.

DeGregori J, Kowalik T, Nevins J . Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol. 1995; 15(8):4215-24. PMC: 230660. DOI: 10.1128/MCB.15.8.4215. View

16.

Van Lint C, Emiliani S, Verdin E . The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996; 5(4-5):245-53. PMC: 6138027. View

17.

Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P . Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2004; 11(1):77-84. DOI: 10.1038/nm1161. View

18.

Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A . Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2004; 11(1):71-6. DOI: 10.1038/nm1160. View

19.

Shankar S, Singh T, Fandy T, Luetrakul T, Ross D, Srivastava R . Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med. 2005; 16(6):1125-38. View

20.

Pink J, Tagliarino C, Planchon S, Yang X, Froelich C, Boothman D . Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis. Exp Cell Res. 2000; 255(2):144-55. DOI: 10.1006/excr.1999.4790. View